The Karmanos Cancer Institute (KCI) requests support in annual Developmental Funds to allow (1) recruitment of new basic and translational investigators, (2) support for innovative projects that bridge several areas of research and (3) support for new shared resources. KCrs developmental funds (non-CCSG in the past cycle) have been used in response to the advice of the External Advisory Board, and the senior leadership of the Center, to enhance the strengths of the current scientific programs and to increase utilization of the Shared Resources. The Developmental Funds are critical to leverage the support of key Wayne State University stakeholders and Detroit philanthropists. The Institute will re-start its very successful Virtual Discovery Grant program in order to stimulate proposals that have a high potential to go on to program project or SPORE funding proposals. As the Population Studies and Prevention Program continues its new emphasis on communication between and among patients, family members, physicians and communities (under the direction of Dr. Terrance Albrecht) it is critical that a new shared resource be developed that can support the unique technical requirements of these trials. A Behavioral and Field Research Core is currently under development in response to this need.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA022453-25
Application #
7310834
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2005-12-01
Budget End
2006-11-30
Support Year
25
Fiscal Year
2006
Total Cost
$195,027
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562
Vaishampayan, Ulka N; Podgorski, Izabela; Heilbrun, Lance K et al. (2018) Biomarkers and Bone Imaging Dynamics Associated with Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res :
Mills, Anne M; Peres, Lauren C; Meiss, Alice et al. (2018) Targetable Immune Regulatory Molecule Expression in High-Grade Serous Ovarian Carcinomas in African American Women: A Study of PD-L1 and IDO in 112 Cases From the African American Cancer Epidemiology Study (AACES). Int J Gynecol Pathol :
Campbell, Douglas H; Lund, Maria E; Nocon, Aline L et al. (2018) Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer. PLoS One 13:e0196017
Sexton, Rachel E; Hachem, Ali H; Assi, Ali A et al. (2018) Metabotropic glutamate receptor-1 regulates inflammation in triple negative breast cancer. Sci Rep 8:16008

Showing the most recent 10 out of 826 publications